These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4208343)

  • 1. A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity.
    Langlois KJ; Forbes JA; Bell GW; Grant GF
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):289-96. PubMed ID: 4208343
    [No Abstract]   [Full Text] [Related]  

  • 2. Double-blind comparison of efficacy, safety, and side effects of Bionamin, phentermine compound, and placebo in the treatment of exogenous obesity.
    Cohen A; De Felice EA; Leb SM; Fuentes JG; Rothwell KG; Truant AP
    Curr Ther Res Clin Exp; 1968 Jul; 10(7):323-34. PubMed ID: 4969672
    [No Abstract]   [Full Text] [Related]  

  • 3. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study.
    Truant AP; Olon LP; Cobb S
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):726-38. PubMed ID: 4629111
    [No Abstract]   [Full Text] [Related]  

  • 5. Double-blind trial of anorectic agents.
    Sproule BC
    Med J Aust; 1969 Feb; 1(8):394-5. PubMed ID: 4889477
    [No Abstract]   [Full Text] [Related]  

  • 6. Weight reduction in osteoarthritis using phentermine.
    Willims RA; Foulsham BM
    Practitioner; 1981 Feb; 225(1352):231-2. PubMed ID: 7022428
    [No Abstract]   [Full Text] [Related]  

  • 7. [L-thyroxine propylhexedrine in the treatment of obesity. Crossed double blind study].
    González Barranco J; Rull JA; Lozano Castañeda O
    Prensa Med Mex; 1974; 39(5-6):298-9. PubMed ID: 4612507
    [No Abstract]   [Full Text] [Related]  

  • 8. A double blind clinical evaluation of a phenylpropanolamine-caffeine-vitamine combination and a placebo in the treatment of exogenous obesity.
    Griboff SI; Berman R
    Curr Ther Res Clin Exp; 1975 Jun; 17(6):535-43. PubMed ID: 808376
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical evaluation of chlorphentermine hydrochloride in a college population.
    Trickett PC; Weir JH
    Pac Med Surg; 1968; 76(1):35-9. PubMed ID: 5294010
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice.
    Vallé-Jones JC; Brodie NH; O'Hara H; O'Hara J; McGhie RL
    Pharmatherapeutica; 1983; 3(5):300-4. PubMed ID: 6844367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Model for clinico-pharmacological experimentation with an appetite depressant. Clinical trial with a delayed-action preparation].
    Strata A; Cucurachi L; Cucurachi P; Dell'anna A; Zuliani U
    Clin Ter; 1968 Mar; 44(6):495-516. PubMed ID: 4899457
    [No Abstract]   [Full Text] [Related]  

  • 12. [Evaluation of an "anorexic" drug (phentermine-resin) in the treatment of obesity].
    Benedetti A; Busonera G; Cattano G
    Policlinico Prat; 1967 Nov; 74(48):1613-9. PubMed ID: 5611163
    [No Abstract]   [Full Text] [Related]  

  • 13. An evaluation of behavioral techniques reinforced with an anorectic drug in a double-blind weight loss study.
    Abramson R; Garg M; Cioffari A; Rotman PA
    J Clin Psychiatry; 1980 Jul; 41(7):234-7. PubMed ID: 6993445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind clinical evaluation of mazindol, dextroamphetamine, and placebo in treatment of exogenous obesity.
    Defelice EA; Chaykin LB; Cohen A
    Curr Ther Res Clin Exp; 1973 Jul; 15(7):358-66. PubMed ID: 4198296
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of obesity. The initial and continued effectiveness of tenuate in intermittent therapy of moderately and severely obese patients. Double-blind study].
    Albach E; Gianoli AC
    Fortschr Med; 1977 Sep; 95(33):2040-4. PubMed ID: 334650
    [No Abstract]   [Full Text] [Related]  

  • 16. Orlistat for obesity.
    Med Lett Drugs Ther; 1999 Jun; 41(1055):55-6. PubMed ID: 10436767
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
    Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG
    Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].
    Riesco J; Troncoso G; Costamaillere L; Rodríguez J
    Rev Med Chil; 1977 Jun; 105(6):375-9. PubMed ID: 331428
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical experience with the use of phenyltert-butylamine (phentermine) as an appetite depressant in the treatment of obesity].
    Lobato DS; da Silveira DD
    Hospital (Rio J); 1966 Nov; 70(5):1343-50. PubMed ID: 5301950
    [No Abstract]   [Full Text] [Related]  

  • 20. How physician obesity specialists use drugs to treat obesity.
    Hendricks EJ; Rothman RB; Greenway FL
    Obesity (Silver Spring); 2009 Sep; 17(9):1730-5. PubMed ID: 19300434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.